MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720

被引:92
作者
Jiang, Chen Chen [1 ]
Lai, Fritz [1 ]
Thorne, Rick F. [1 ]
Yang, Fan [1 ]
Liu, Hao [1 ]
Hersey, Peter [1 ]
Zhang, Xu Dong [1 ]
机构
[1] Immunol & Oncol Unit, Newcastle, NSW 2300, Australia
基金
英国医学研究理事会;
关键词
PROTEIN-KINASE PATHWAY; CUTANEOUS MELANOMA; BRAF; FEEDBACK; ACTIVATION; MUTATIONS; INDUCTION; BIM;
D O I
10.1158/1078-0432.CCR-10-2225
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To examine mechanisms that determine long-term responses of B-RAF(V600E) melanoma cells to B-RAF inhibitors. Experimental Design: B-RAF(V600E) melanoma cells were exposed to the B-RAF inhibitor PLX4720 for prolonged periods to select for cells resistant to apoptosis induced by the inhibitor. The resultant cells were analyzed for activation of extracellular signal regulated kinase (ERK), MAP/ERK kinase (MEK), and Akt, and related signals. Their roles in survival of the cells were also examined. Results: B-RAF(V600E) melanoma cells selected for resistant to PLX4720-induced apoptosis retained the V600E mutation in B-RAF, and proliferated steadily in the presence of the inhibitor, albeit with slow growth rate. These cells displayed high levels of ERK activation, that is, at least in part, independent of the conventional RAF/MEK/ERK pathway, as MEK activation was low and inhibition of MEK did not significantly block activation of ERK. In contrast, extracellular signals appeared involved. This was associated with elevated activation of the phosphoinositide 3-kinase (PI3k)/Akt pathway and could be inhibited by serum starvation and inhibition of PI3k/Akt. Inhibition of MEK did not impact on survival of these cells, whereas serum starvation, inhibition of PI3K/Akt, and inhibition of ERK1/2 reduced their viability. Conclusions: These results indicate that sensitivity to induction of apoptosis may be a major determinant of long-term responses of B-RAF(V600E) melanomas to specific inhibitors and suggest that rebound melanoma growth after initial treatment with the inhibitors may not be responsive to MEK inhibitors, but may be susceptible to inhibition of the PI3k/Akt pathway. Clin Cancer Res; 17(4); 721-30. (C) 2010 AACR.
引用
收藏
页码:721 / 730
页数:10
相关论文
共 37 条
[1]   PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells [J].
Aksamitiene, Edita ;
Kholodenko, Boris N. ;
Kolch, Walter ;
Hoek, Jan B. ;
Kiyatkin, Anatoly .
CELLULAR SIGNALLING, 2010, 22 (09) :1369-1378
[2]  
Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397
[3]   Tumour cell survival signalling by the ERK1/2 pathway [J].
Balmanno, K. ;
Cook, S. J. .
CELL DEATH AND DIFFERENTIATION, 2009, 16 (03) :368-377
[4]   Spatiotemporal regulation of ERK2 by dual specificity phosphatases [J].
Caunt, Christopher J. ;
Armstrong, Stephen P. ;
Rivers, Caroline A. ;
Norman, Michael R. ;
McArdle, Craig A. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (39) :26612-26623
[5]   Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032 [J].
Chapman, P. ;
Puzanov, I. ;
Sosman, J. ;
Kim, K. ;
Ribas, A. ;
McArthur, G. ;
Lee, R. ;
Grippo, J. ;
Nolop, K. ;
Flaherty, K. .
EJC SUPPLEMENTS, 2009, 7 (03) :5-5
[6]   Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V600E) B-RAF [J].
Christensen, C ;
Guldberg, P .
ONCOGENE, 2005, 24 (41) :6292-6302
[7]   Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic [J].
Cragg, Mark S. ;
Jansen, Elisa S. ;
Cook, Michele ;
Harris, Claire ;
Strasser, Andreas ;
Scott, Clare L. .
JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (11) :3651-3659
[8]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[9]   MEK1 mutations confer resistance to MEK and B-RAF inhibition [J].
Emery, Caroline M. ;
Vijayendran, Krishna G. ;
Zipser, Marie C. ;
Sawyer, Allison M. ;
Niu, Lili ;
Kim, Jessica J. ;
Hatton, Charles ;
Chopra, Rajiv ;
Oberholzer, Patrick A. ;
Karpova, Maria B. ;
MacConaill, Laura E. ;
Zhang, Jianming ;
Gray, Nathanael S. ;
Sellers, William R. ;
Dummer, Reinhard ;
Garraway, Levi A. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (48) :20411-20416
[10]  
FLAHERTY K, 2009, J CLIN ONCOL S, V27, pNIL18